Cargando…

Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide

An understanding of the interaction between the antibody and its targeted antigen and knowing of the epitopes are critical for the development of monoclonal antibody drugs. Complement factor H (CFH) is implied to play a role in tumor growth and metastasis. An autoantibody to CHF is associated with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bing, Lin, Shu-Jian, Ren, Jia-Yi, Liu, Tong, Wang, Yue-Ming, Li, Cheng-Ming, Xu, Wen-Wen, He, You-Wen, Zheng, Wei-Hong, Zhao, Jian, Yuan, Xiao-Hui, Liao, Hua-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566401/
https://www.ncbi.nlm.nih.gov/pubmed/31130605
http://dx.doi.org/10.3390/ijms20102568
_version_ 1783426844076277760
author Yang, Bing
Lin, Shu-Jian
Ren, Jia-Yi
Liu, Tong
Wang, Yue-Ming
Li, Cheng-Ming
Xu, Wen-Wen
He, You-Wen
Zheng, Wei-Hong
Zhao, Jian
Yuan, Xiao-Hui
Liao, Hua-Xin
author_facet Yang, Bing
Lin, Shu-Jian
Ren, Jia-Yi
Liu, Tong
Wang, Yue-Ming
Li, Cheng-Ming
Xu, Wen-Wen
He, You-Wen
Zheng, Wei-Hong
Zhao, Jian
Yuan, Xiao-Hui
Liao, Hua-Xin
author_sort Yang, Bing
collection PubMed
description An understanding of the interaction between the antibody and its targeted antigen and knowing of the epitopes are critical for the development of monoclonal antibody drugs. Complement factor H (CFH) is implied to play a role in tumor growth and metastasis. An autoantibody to CHF is associated with anti-tumor cell activity. The interaction of a human monoclonal antibody Ab42 that was isolated from a cancer patient with CFH polypeptide (pCFH) antigen was analyzed by molecular docking, molecular dynamics (MD) simulation, free energy calculation, and computational alanine scanning (CAS). Experimental alanine scanning (EAS) was then carried out to verify the results of the theoretical calculation. Our results demonstrated that the Ab42 antibody interacts with pCFH by hydrogen bonds through the Tyr315, Ser100, Gly33, and Tyr53 residues on the complementarity-determining regions (CDRs), respectively, with the amino acid residues of Pro441, Ile442, Asp443, Asn444, Ile447, and Thr448 on the pCFH antigen. In conclusion, this study has explored the mechanism of interaction between Ab42 antibody and its targeted antigen by both theoretical and experimental analysis. Our results have important theoretical significance for the design and development of relevant antibody drugs.
format Online
Article
Text
id pubmed-6566401
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65664012019-06-17 Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide Yang, Bing Lin, Shu-Jian Ren, Jia-Yi Liu, Tong Wang, Yue-Ming Li, Cheng-Ming Xu, Wen-Wen He, You-Wen Zheng, Wei-Hong Zhao, Jian Yuan, Xiao-Hui Liao, Hua-Xin Int J Mol Sci Article An understanding of the interaction between the antibody and its targeted antigen and knowing of the epitopes are critical for the development of monoclonal antibody drugs. Complement factor H (CFH) is implied to play a role in tumor growth and metastasis. An autoantibody to CHF is associated with anti-tumor cell activity. The interaction of a human monoclonal antibody Ab42 that was isolated from a cancer patient with CFH polypeptide (pCFH) antigen was analyzed by molecular docking, molecular dynamics (MD) simulation, free energy calculation, and computational alanine scanning (CAS). Experimental alanine scanning (EAS) was then carried out to verify the results of the theoretical calculation. Our results demonstrated that the Ab42 antibody interacts with pCFH by hydrogen bonds through the Tyr315, Ser100, Gly33, and Tyr53 residues on the complementarity-determining regions (CDRs), respectively, with the amino acid residues of Pro441, Ile442, Asp443, Asn444, Ile447, and Thr448 on the pCFH antigen. In conclusion, this study has explored the mechanism of interaction between Ab42 antibody and its targeted antigen by both theoretical and experimental analysis. Our results have important theoretical significance for the design and development of relevant antibody drugs. MDPI 2019-05-25 /pmc/articles/PMC6566401/ /pubmed/31130605 http://dx.doi.org/10.3390/ijms20102568 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yang, Bing
Lin, Shu-Jian
Ren, Jia-Yi
Liu, Tong
Wang, Yue-Ming
Li, Cheng-Ming
Xu, Wen-Wen
He, You-Wen
Zheng, Wei-Hong
Zhao, Jian
Yuan, Xiao-Hui
Liao, Hua-Xin
Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
title Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
title_full Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
title_fullStr Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
title_full_unstemmed Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
title_short Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
title_sort molecular docking and molecular dynamics (md) simulation of human anti-complement factor h (cfh) antibody ab42 and cfh polypeptide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566401/
https://www.ncbi.nlm.nih.gov/pubmed/31130605
http://dx.doi.org/10.3390/ijms20102568
work_keys_str_mv AT yangbing moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT linshujian moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT renjiayi moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT liutong moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT wangyueming moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT lichengming moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT xuwenwen moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT heyouwen moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT zhengweihong moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT zhaojian moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT yuanxiaohui moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide
AT liaohuaxin moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide